

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Barnes Alane P</u> _____ (Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200 _____ (Street) DURHAM NC 27703 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIOCRYST PHARMACEUTICALS INC [</u> <u>BCRX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>VP, General Counsel & Corp Sec</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/01/2014</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/01/2014		F		1,090 ⁽¹⁾	D	\$11.69	81,182	D	
Common Stock	03/04/2014		M		12,500	A	\$4.73	93,682	D	
Common Stock	03/04/2014		M		6,156	A	\$6.68	99,838	D	
Common Stock	03/04/2014		M		2,518	A	\$4.15	102,356	D	
Common Stock	03/04/2014		M		10,000	A	\$1.42	112,356	D	
Common Stock	03/04/2014		S		40,734	D	\$12.63 ⁽²⁾	71,622	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Emp. Stock Option (Right to Buy)	\$4.73	03/04/2014		M			12,500	03/01/2013	03/01/2022	Common Stock	12,500	\$0	37,500	D	
Emp. Stock Option (Right to Buy)	\$6.68	03/04/2014		M			6,156	03/01/2011	03/01/2020	Common Stock	6,156	\$0	35,844	D	
Emp. Stock Option (Right to Buy)	\$4.15	03/04/2014		M			2,518	03/01/2012	03/01/2021	Common Stock	2,518	\$0	27,482	D	
Emp. Stock Option (Right to Buy)	\$1.42	03/04/2014		M			10,000	01/01/2014	01/01/2023	Common Stock	10,000	\$0	90,000	D	

Explanation of Responses:

- Shares withheld by BioCryst Pharmaceuticals, Inc. upon the vesting of restricted stock to satisfy the reporting person's tax withholding obligations.
- The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$12.44 to \$12.99. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

/s/ Alane P. Barnes, by power 03/07/2014
of attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.